Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education
May 05 2022 - 7:30AM
Biofrontera Inc. (Nasdaq:
BFRI), a biopharmaceutical company specializing in the
commercialization of dermatological products, announced today its
sponsorship of the 17th Edition of the Music City Symposium for
Cosmetic Advances & Laser Education (SCALE), being held May
11-15, 2022 in Nashville, Tenn. As a Sponsor, Biofrontera will be
hosting a booth showcasing its innovative, FDA-approved products
and featuring its new RhodoLED® XL illumination lamp used in
photodynamic therapy (PDT) for treating actinic keratosis (AK). On
Saturday, May 14, 2022, Dr. Michael Gold, M.D., a board-certified
dermatologist, cosmetic surgeon and founder of Gold Skin Care
Center in Nashville, will present a live demonstration of RhodoLED
XL during the “Live Lasers and EBDs On Stage” session of the
Symposium.
Music City SCALE is considered a premier
multidisciplinary meeting for aesthetic medicine, plastic surgery
and medical dermatology. This is the first domestic medical
conference where the RhodoLED® XL lamp will be featured.
“The Biofrontera team looks forward to meeting
with dermatologists and healthcare providers, presenting the
benefits of Ameluz® in combination with BF-RhodoLED® and showcasing
our new, larger RhodoLED® XL PDT lamp among the latest treatments
and breakthroughs in medical dermatology and aesthetics. RhodoLED®
XL, which was approved in combination with Ameluz® for the
treatment of mild and moderate AK on the scalp, allows for the
illumination of a larger skin area, thereby enabling simultaneous
treatment of AK lesions that are distant from one another. We
remain on track with our plans to launch XL by the end of the
year,” stated Hermann Lübbert, Executive Chairman of Biofrontera
Inc.
Additionally, Biofrontera recognizes May as Skin
Cancer Awareness Month through its support of education-focused
initiatives. Biofrontera announced its participation in the Noah
Worcester Dermatological Society Conference from May 4-8 in
Newport, R.I. as part of its strategic initiative to strengthen
medical affairs and education. The Company will also be attending
The Skin Cancer Foundation’s Champions for Change Gala 2022 on May
12th in New York, with proceeds from the fundraiser supporting
lifesaving educational campaigns, community programs and research
initiatives.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on PDT and topical antibiotics. The
Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as
impetigo, a bacterial skin infection. For more information, visit
www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the Company’s business and marketing
strategy, future operations and business, future financial
position, potential to expand the label of Ameluz®, expected
revenue growth, expected cash flow for operations, expected total
revenues, projections constituting the financial guidance included
in this release and statements about the commercial focus of
Biofrontera Inc. throughout the year and expected increases in the
Company’s sales force. We have based these forward-looking
statements on our current expectations and projections about future
events, nevertheless, actual results or events could differ
materially from the plans, intentions and expectations disclosed
in, or implied by, the forward-looking statements we make. These
risks and uncertainties, many of which are beyond our control,
including, but not limited to, the impact of extraordinary external
events, such as the current COVID-19 pandemic; any changes in the
Company’s relationship with its licensors; the ability of the
Company’s licensors to fulfill their obligations to the Company in
a timely manner; the Company’s ability to achieve and sustain
profitability; whether the current global disruptions in supply
chains will impact the Company’s ability to obtain and distribute
its licensed products; changes in the practices of healthcare
providers, including any changes to the coverage, reimbursement and
pricing for procedures using the Company’s licensed products; the
uncertainties inherent in the initiation and conduct of clinical
trials; availability and timing of data from clinical trials;
whether results of earlier clinical trials or trials of Ameluz® in
combination with BF-RhodoLED® in different disease indications or
product applications will be indicative of the results of ongoing
or future trials; uncertainties associated with regulatory review
of clinical trials and applications for marketing approvals;
whether the market opportunity for Ameluz® in combination with
BF-RhodoLED® is consistent with the Company’s expectations; the
Company’s ability to complete the transition to a public company;
the Company’s ability to retain and hire key personnel; the
sufficiency of cash resources and need for additional financing and
other factors that may be disclosed in the Company’s filings with
the SEC, which can be obtained on the SEC website at www.sec.gov.
Readers are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations and beliefs. The Company does not plan to
update any such forward-looking statements and expressly disclaims
any duty to update the information contained in this press release
except as required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Oct 2023 to Oct 2024